Gan

USAntibiotics Appoints Eric Wesoloski Vice President of Quality and Regulatory Affairs

Retrieved on: 
Thursday, January 11, 2024

USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.

Key Points: 
  • USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.
  • In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company’s antibiotics.
  • With more than 30 years in the life sciences industry, Wesoloski’s experience spans markets that include biologics, nutraceuticals, medical devices and pharmaceuticals.
  • “We are pleased to welcome Eric Wesoloski to USAntibiotics as vice president of quality and regulatory affairs,” said Patrick Cashman, president, USAntibiotics.

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

Retrieved on: 
Friday, October 20, 2023

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren’s syndrome, or SS, today addressed the status of the Company's continued and uninterrupted activity in Israel against the background of the recent severe terrorist attack in the south of the country and the subsequent declaration of war by the Israeli government against the Hamas terrorist organization.

Key Points: 
  • Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren’s syndrome, or SS, today addressed the status of the Company's continued and uninterrupted activity in Israel against the background of the recent severe terrorist attack in the south of the country and the subsequent declaration of war by the Israeli government against the Hamas terrorist organization.
  • XTL’s management confirms that to date the Company has not seen any adverse impact to its ongoing operations in Israel and continues to work as normal.
  • At the same time, the Company continues to monitor its ongoing activities and make any needed adjustments to ensure a smooth continuity of its business.
  • The Company notes that its headquarters are in the center of the country, near Tel Aviv, and not near any borders.

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Retrieved on: 
Friday, October 20, 2023

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Key Points: 
  • Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
  • Based on the closing bid price of the Company's American Depositary Shares (“ADSs”) for the 30 consecutive business days from September 6, 2023, to October 17, 2023, the Company no longer meets the minimum bid price requirement.
  • The Notice states that to regain compliance, the bid price for the ADSs must close at $1.00 per ADS or more (the "Minimum Bid Price") for a minimum of ten (10) consecutive business days during the compliance period ending April 15, 2024.
  • However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price or maintain compliance with other Nasdaq listing standards.

Creators Earn Higher Revenue Shares with Gan Jing World's Membership Channel Subscription - Earn income on videos, lives and even articles!

Retrieved on: 
Tuesday, October 24, 2023

Gan Jing World (GJW) is gearing up to roll out a suite of highly anticipated monetization tools that allow you to now earn income on the fastest-growing social platform.

Key Points: 
  • Gan Jing World (GJW) is gearing up to roll out a suite of highly anticipated monetization tools that allow you to now earn income on the fastest-growing social platform.
  • Gan Jing World has soft launched the Channel Membership Program (Beta), offering content creators the option of enabling paid subscriptions to videos, live streams, and articles.
  • In the coming months, the program will be opened to all eligible channel owners on GanJingWorld.com
    And the best part?
  • GJW will soon also introduce an Ad-Revenue Sharing Program to provide additional income streams for creators by the end of 2023.

Viewbix Reports its Consolidated Financial Results for the First Half and the Second Quarter of 2023 with Revenues Totaling $48 Million for the First Half of 2023

Retrieved on: 
Monday, August 14, 2023

Viewbix’s second quarter results of 2023 underscore the Company’s continued growth, demonstrated by an 18% increase in revenues as compared to its second quarter in 2022.

Key Points: 
  • Viewbix’s second quarter results of 2023 underscore the Company’s continued growth, demonstrated by an 18% increase in revenues as compared to its second quarter in 2022.
  • In the second quarter of 2023, revenues amounted to $27,154 thousand, an increase of 18.5% as compared to the second quarter of 2022.
  • In the second quarter of 2023, operating income amounted to $250 thousand as compared to operating income of $761 thousand in the second quarter of 2022.
  • Net cash from operating activities for the first half of 2023 amounted to $1,015 thousand compared to $598 thousand in the first half of 2022.

A POWERFUL NEW MULTIMEDIA TOOL EXPANDS CONTENT CREATORS' FAN FOLLOWERS AND ENRICHES COMMUNITY INTERACTIONS

Retrieved on: 
Thursday, July 20, 2023

Influencers and content creators can launch their own Hashtag Campaigns, building a panoramic view into their topics and events that sees the world through fans' eyes.

Key Points: 
  • Influencers and content creators can launch their own Hashtag Campaigns, building a panoramic view into their topics and events that sees the world through fans' eyes.
  • A dedicated page will be automatically created and the aggregation tool will conveniently display all forms of content submitted with that hashtag.
  • The multimedia feature leverages technology as a tool, instead of as an exclusive feature of its platform, placing the topic of interest at the center.
  • For more information, visit Send2Press Newswire at https://www.Send2Press.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/a-powerful-new-multimedia-tool-...

Gan Jing World Celebrates Mother's Day Videos Award

Retrieved on: 
Thursday, May 11, 2023

MIDDLETOWN, N.Y., May 11, 2023 /PRNewswire/ -- Gan Jing World (Ganjingworld Corp.) announces its first Mother's Day celebration videos award that showcases the best memories, moments, traits, and values.

Key Points: 
  • MIDDLETOWN, N.Y., May 11, 2023 /PRNewswire/ -- Gan Jing World (Ganjingworld Corp.) announces its first Mother's Day celebration videos award that showcases the best memories, moments, traits, and values.
  • It allows videos, articles, and pictures sharing environment at Gan Jing World .
  • Gan Jing World (GJW) is a dynamic network of integrated services featuring a video-sharing platform, a pristine online reading section, topic discussion board, and dedicated children's space.
  • Launched in June 2022, Gan Jing World is making exponential growth.

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
Sunday, January 22, 2023

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.